BofA raises target for Qiagen stock from USD 49 to USD 50

Published on 10/12/2026 at 09:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock costs EUR 40.58 on October 12, 2026 versus EUR 40.19. Second-quarter revenue was USD 535.04 million, up 8.68 percent sequentially.

Key points in brief

BofA raised its Qiagen price target from USD 49.00 to USD 50.00 on October 9, 2026 and kept a Buy rating.
Qiagen launched IPA Investigator and the QIAGEN Discovery Platform on October 6, 2026.
Qiagen stock was at EUR 40.58 at Lang & Schwarz on October 12, 2026, up 0.97 percent versus the October 9 Xetra close of EUR 40.19.
Second-quarter 2026 revenue reached USD 535.04 million, up 8.68 percent from the first quarter of 2026.
Qiagen is scheduled to report third-quarter results on November 4, 2026.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

BofA raised its price target for Qiagen stock from USD 49.00 to USD 50.00 on October 9, 2026 and kept a Buy rating, according to Markets Insider. Qiagen stock was at EUR 40.58 at Lang & Schwarz on October 12, 2026, 0.97 percent above the Xetra close of October 9, 2026 at EUR 40.19.

Qiagen's three recent product steps

On September 24, 2026, Qiagen launched QIAmini, an automated sample preparation system designed for smaller research batches, according to Simply Wall St. The report said the company estimates a potential market of more than 100,000 instrument placements worldwide.

On September 28, 2026, Qiagen expanded its QIAstat-Dx bloodstream infection portfolio to 33 pathogen targets and 28 antimicrobial resistance markers, according to Simply Wall St. On October 6, 2026, the company announced IPA Investigator and the QIAGEN Discovery Platform for research and drug discovery, according to Qiagen.

What does AI add to growth?

Qiagen said the October 6 launches build on more than 25 years of biomedical knowledge and combine natural-language research tools with expert-reviewed evidence. The platforms are aimed at research and automated drug discovery, extending the company beyond sample preparation and molecular diagnostics.

The financial base is also measurable. Second-quarter 2026 revenue was USD 535.04 million, compared with USD 492.32 million in the first quarter of 2026, an 8.68 percent sequential increase. Diluted earnings per share were USD 0.50 and net income was USD 103.40 million in the second quarter of 2026.

Next date on the calendar

Qiagen is scheduled to report third-quarter results on November 4, 2026, according to Yahoo Finance. That date gives the market a defined checkpoint for judging whether product launches and automation can support the company's 2026 performance.

Stock remains below its yearly high

Qiagen's primary listing is on the NYSE, where the October 9, 2026 quote was USD 45.38 and the 52-week range was USD 32.53 to USD 57.82. The market capitalization was USD 9.4 billion on October 9, 2026, while the company's second-quarter operating cash flow reached USD 200.69 million.

For German investors, the Lang & Schwarz price of EUR 40.58 was in trading on October 12, 2026 at 9:15 a.m. CEST. The move was 0.97 percent above the Xetra close of October 9, 2026 at EUR 40.19, keeping the daily change below the threshold for a directional headline. The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.